Market Intelligence chevron_right Pharma & Healthcare chevron_right Chronic Hepatitis B Oral Drugs
Global Report 2024

Global Chronic Hepatitis B Oral Drugs Market Growth 2024-2030

calendar_todayPublished: Apr 2024 descriptionPages: 136 categoryCategory: Pharma & Healthcare
1 Scope of the Report

    1.1 Market Introduction

    1.2 Years Considered

    1.3 Research Objectives

    1.4 Market Research Methodology

    1.5 Research Process and Data Source

    1.6 Economic Indicators

    1.7 Currency Considered

    1.8 Market Estimation Caveats

2 Executive Summary

    2.1 World Market Overview

        2.1.1 Global Chronic Hepatitis B Oral Drugs Annual Sales 2019-2030

        2.1.2 World Current & Future Analysis for Chronic Hepatitis B Oral Drugs by Geographic Region, 2019, 2023 & 2030

        2.1.3 World Current & Future Analysis for Chronic Hepatitis B Oral Drugs by Country/Region, 2019, 2023 & 2030

    2.2 Chronic Hepatitis B Oral Drugs Segment by Type

        2.2.1 Entecavir

        2.2.2 Tenofovir

        2.2.3 Lamivudine

        2.2.4 Adefovir

        2.2.5 Telbivudine

        2.2.6 Others

    2.3 Chronic Hepatitis B Oral Drugs Sales by Type

        2.3.1 Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

        2.3.2 Global Chronic Hepatitis B Oral Drugs Revenue and Market Share by Type (2019-2024)

        2.3.3 Global Chronic Hepatitis B Oral Drugs Sale Price by Type (2019-2024)

    2.4 Chronic Hepatitis B Oral Drugs Segment by Application

        2.4.1 Hospital

        2.4.2 Clinic

        2.4.3 Others

    2.5 Chronic Hepatitis B Oral Drugs Sales by Application

        2.5.1 Global Chronic Hepatitis B Oral Drugs Sale Market Share by Application (2019-2024)

        2.5.2 Global Chronic Hepatitis B Oral Drugs Revenue and Market Share by Application (2019-2024)

        2.5.3 Global Chronic Hepatitis B Oral Drugs Sale Price by Application (2019-2024)

3 Global Chronic Hepatitis B Oral Drugs by Company

    3.1 Global Chronic Hepatitis B Oral Drugs Breakdown Data by Company

        3.1.1 Global Chronic Hepatitis B Oral Drugs Annual Sales by Company (2019-2024)

        3.1.2 Global Chronic Hepatitis B Oral Drugs Sales Market Share by Company (2019-2024)

    3.2 Global Chronic Hepatitis B Oral Drugs Annual Revenue by Company (2019-2024)

        3.2.1 Global Chronic Hepatitis B Oral Drugs Revenue by Company (2019-2024)

        3.2.2 Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Company (2019-2024)

    3.3 Global Chronic Hepatitis B Oral Drugs Sale Price by Company

    3.4 Key Manufacturers Chronic Hepatitis B Oral Drugs Producing Area Distribution, Sales Area, Product Type

        3.4.1 Key Manufacturers Chronic Hepatitis B Oral Drugs Product Location Distribution

        3.4.2 Players Chronic Hepatitis B Oral Drugs Products Offered

    3.5 Market Concentration Rate Analysis

        3.5.1 Competition Landscape Analysis

        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

    3.6 New Products and Potential Entrants

    3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Chronic Hepatitis B Oral Drugs by Geographic Region

    4.1 World Historic Chronic Hepatitis B Oral Drugs Market Size by Geographic Region (2019-2024)

        4.1.1 Global Chronic Hepatitis B Oral Drugs Annual Sales by Geographic Region (2019-2024)

        4.1.2 Global Chronic Hepatitis B Oral Drugs Annual Revenue by Geographic Region (2019-2024)

    4.2 World Historic Chronic Hepatitis B Oral Drugs Market Size by Country/Region (2019-2024)

        4.2.1 Global Chronic Hepatitis B Oral Drugs Annual Sales by Country/Region (2019-2024)

        4.2.2 Global Chronic Hepatitis B Oral Drugs Annual Revenue by Country/Region (2019-2024)

    4.3 Americas Chronic Hepatitis B Oral Drugs Sales Growth

    4.4 APAC Chronic Hepatitis B Oral Drugs Sales Growth

    4.5 Europe Chronic Hepatitis B Oral Drugs Sales Growth

    4.6 Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Growth

5 Americas

    5.1 Americas Chronic Hepatitis B Oral Drugs Sales by Country

        5.1.1 Americas Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024)

        5.1.2 Americas Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024)

    5.2 Americas Chronic Hepatitis B Oral Drugs Sales by Type

    5.3 Americas Chronic Hepatitis B Oral Drugs Sales by Application

    5.4 United States

    5.5 Canada

    5.6 Mexico

    5.7 Brazil

6 APAC

    6.1 APAC Chronic Hepatitis B Oral Drugs Sales by Region

        6.1.1 APAC Chronic Hepatitis B Oral Drugs Sales by Region (2019-2024)

        6.1.2 APAC Chronic Hepatitis B Oral Drugs Revenue by Region (2019-2024)

    6.2 APAC Chronic Hepatitis B Oral Drugs Sales by Type

    6.3 APAC Chronic Hepatitis B Oral Drugs Sales by Application

    6.4 China

    6.5 Japan

    6.6 South Korea

    6.7 Southeast Asia

    6.8 India

    6.9 Australia

    6.10 China Taiwan

7 Europe

    7.1 Europe Chronic Hepatitis B Oral Drugs by Country

        7.1.1 Europe Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024)

        7.1.2 Europe Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024)

    7.2 Europe Chronic Hepatitis B Oral Drugs Sales by Type

    7.3 Europe Chronic Hepatitis B Oral Drugs Sales by Application

    7.4 Germany

    7.5 France

    7.6 UK

    7.7 Italy

    7.8 Russia

8 Middle East & Africa

    8.1 Middle East & Africa Chronic Hepatitis B Oral Drugs by Country

        8.1.1 Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024)

        8.1.2 Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024)

    8.2 Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Type

    8.3 Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Application

    8.4 Egypt

    8.5 South Africa

    8.6 Israel

    8.7 Turkey

    8.8 GCC Countries

9 Market Drivers, Challenges and Trends

    9.1 Market Drivers & Growth Opportunities

    9.2 Market Challenges & Risks

    9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

    10.1 Raw Material and Suppliers

    10.2 Manufacturing Cost Structure Analysis of Chronic Hepatitis B Oral Drugs

    10.3 Manufacturing Process Analysis of Chronic Hepatitis B Oral Drugs

    10.4 Industry Chain Structure of Chronic Hepatitis B Oral Drugs

11 Marketing, Distributors and Customer

    11.1 Sales Channel

        11.1.1 Direct Channels

        11.1.2 Indirect Channels

    11.2 Chronic Hepatitis B Oral Drugs Distributors

    11.3 Chronic Hepatitis B Oral Drugs Customer

12 World Forecast Review for Chronic Hepatitis B Oral Drugs by Geographic Region

    12.1 Global Chronic Hepatitis B Oral Drugs Market Size Forecast by Region

        12.1.1 Global Chronic Hepatitis B Oral Drugs Forecast by Region (2025-2030)

        12.1.2 Global Chronic Hepatitis B Oral Drugs Annual Revenue Forecast by Region (2025-2030)

    12.2 Americas Forecast by Country

    12.3 APAC Forecast by Region

    12.4 Europe Forecast by Country

    12.5 Middle East & Africa Forecast by Country

    12.6 Global Chronic Hepatitis B Oral Drugs Forecast by Type

    12.7 Global Chronic Hepatitis B Oral Drugs Forecast by Application

13 Key Players Analysis

    13.1 GSK

        13.1.1 GSK Company Information

        13.1.2 GSK Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.1.3 GSK Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.1.4 GSK Main Business Overview

        13.1.5 GSK Latest Developments

    13.2 Bristol Myers Squibb

        13.2.1 Bristol Myers Squibb Company Information

        13.2.2 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.2.3 Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.2.4 Bristol Myers Squibb Main Business Overview

        13.2.5 Bristol Myers Squibb Latest Developments

    13.3 Gilead Sciences

        13.3.1 Gilead Sciences Company Information

        13.3.2 Gilead Sciences Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.3.3 Gilead Sciences Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.3.4 Gilead Sciences Main Business Overview

        13.3.5 Gilead Sciences Latest Developments

    13.4 Novartis

        13.4.1 Novartis Company Information

        13.4.2 Novartis Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.4.3 Novartis Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.4.4 Novartis Main Business Overview

        13.4.5 Novartis Latest Developments

    13.5 Roche

        13.5.1 Roche Company Information

        13.5.2 Roche Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.5.3 Roche Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.5.4 Roche Main Business Overview

        13.5.5 Roche Latest Developments

    13.6 Merck

        13.6.1 Merck Company Information

        13.6.2 Merck Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.6.3 Merck Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.6.4 Merck Main Business Overview

        13.6.5 Merck Latest Developments

    13.7 Johnson & Johnson

        13.7.1 Johnson & Johnson Company Information

        13.7.2 Johnson & Johnson Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.7.3 Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.7.4 Johnson & Johnson Main Business Overview

        13.7.5 Johnson & Johnson Latest Developments

    13.8 Dawnrays Pharmaceutical

        13.8.1 Dawnrays Pharmaceutical Company Information

        13.8.2 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.8.3 Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.8.4 Dawnrays Pharmaceutical Main Business Overview

        13.8.5 Dawnrays Pharmaceutical Latest Developments

    13.9 Hansoh Pharmaceutical

        13.9.1 Hansoh Pharmaceutical Company Information

        13.9.2 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.9.3 Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.9.4 Hansoh Pharmaceutical Main Business Overview

        13.9.5 Hansoh Pharmaceutical Latest Developments

    13.10 Chia Tai-Tianqing Pharmaceutical

        13.10.1 Chia Tai-Tianqing Pharmaceutical Company Information

        13.10.2 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.10.3 Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.10.4 Chia Tai-Tianqing Pharmaceutical Main Business Overview

        13.10.5 Chia Tai-Tianqing Pharmaceutical Latest Developments

    13.11 Qilu pharmaceutical

        13.11.1 Qilu pharmaceutical Company Information

        13.11.2 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.11.3 Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.11.4 Qilu pharmaceutical Main Business Overview

        13.11.5 Qilu pharmaceutical Latest Developments

    13.12 Fujian Cosunter Pharma

        13.12.1 Fujian Cosunter Pharma Company Information

        13.12.2 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.12.3 Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.12.4 Fujian Cosunter Pharma Main Business Overview

        13.12.5 Fujian Cosunter Pharma Latest Developments

    13.13 Xiamen Amoytop Biotech

        13.13.1 Xiamen Amoytop Biotech Company Information

        13.13.2 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.13.3 Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.13.4 Xiamen Amoytop Biotech Main Business Overview

        13.13.5 Xiamen Amoytop Biotech Latest Developments

    13.14 YaoPharma

        13.14.1 YaoPharma Company Information

        13.14.2 YaoPharma Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.14.3 YaoPharma Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.14.4 YaoPharma Main Business Overview

        13.14.5 YaoPharma Latest Developments

    13.15 Kelun Pharmaceutical

        13.15.1 Kelun Pharmaceutical Company Information

        13.15.2 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

        13.15.3 Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

        13.15.4 Kelun Pharmaceutical Main Business Overview

        13.15.5 Kelun Pharmaceutical Latest Developments

14 Research Findings and Conclusion

List of Tables

    Table 1. Chronic Hepatitis B Oral Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)

    Table 2. Chronic Hepatitis B Oral Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)

    Table 3. Major Players of Entecavir

    Table 4. Major Players of Tenofovir

    Table 5. Major Players of Lamivudine

    Table 6. Major Players of Adefovir

    Table 7. Major Players of Telbivudine

    Table 8. Major Players of Others

    Table 9. Global Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024) & (K Units)

    Table 10. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

    Table 11. Global Chronic Hepatitis B Oral Drugs Revenue by Type (2019-2024) & ($ million)

    Table 12. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2019-2024)

    Table 13. Global Chronic Hepatitis B Oral Drugs Sale Price by Type (2019-2024) & (US$/Unit)

    Table 14. Global Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024) & (K Units)

    Table 15. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)

    Table 16. Global Chronic Hepatitis B Oral Drugs Revenue by Application (2019-2024)

    Table 17. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application (2019-2024)

    Table 18. Global Chronic Hepatitis B Oral Drugs Sale Price by Application (2019-2024) & (US$/Unit)

    Table 19. Global Chronic Hepatitis B Oral Drugs Sales by Company (2019-2024) & (K Units)

    Table 20. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Company (2019-2024)

    Table 21. Global Chronic Hepatitis B Oral Drugs Revenue by Company (2019-2024) ($ Millions)

    Table 22. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Company (2019-2024)

    Table 23. Global Chronic Hepatitis B Oral Drugs Sale Price by Company (2019-2024) & (US$/Unit)

    Table 24. Key Manufacturers Chronic Hepatitis B Oral Drugs Producing Area Distribution and Sales Area

    Table 25. Players Chronic Hepatitis B Oral Drugs Products Offered

    Table 26. Chronic Hepatitis B Oral Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

    Table 27. New Products and Potential Entrants

    Table 28. Mergers & Acquisitions, Expansion

    Table 29. Global Chronic Hepatitis B Oral Drugs Sales by Geographic Region (2019-2024) & (K Units)

    Table 30. Global Chronic Hepatitis B Oral Drugs Sales Market Share Geographic Region (2019-2024)

    Table 31. Global Chronic Hepatitis B Oral Drugs Revenue by Geographic Region (2019-2024) & ($ millions)

    Table 32. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Geographic Region (2019-2024)

    Table 33. Global Chronic Hepatitis B Oral Drugs Sales by Country/Region (2019-2024) & (K Units)

    Table 34. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Country/Region (2019-2024)

    Table 35. Global Chronic Hepatitis B Oral Drugs Revenue by Country/Region (2019-2024) & ($ millions)

    Table 36. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Country/Region (2019-2024)

    Table 37. Americas Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)

    Table 38. Americas Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2024)

    Table 39. Americas Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & ($ Millions)

    Table 40. Americas Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2024)

    Table 41. Americas Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024) & (K Units)

    Table 42. Americas Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024) & (K Units)

    Table 43. APAC Chronic Hepatitis B Oral Drugs Sales by Region (2019-2024) & (K Units)

    Table 44. APAC Chronic Hepatitis B Oral Drugs Sales Market Share by Region (2019-2024)

    Table 45. APAC Chronic Hepatitis B Oral Drugs Revenue by Region (2019-2024) & ($ Millions)

    Table 46. APAC Chronic Hepatitis B Oral Drugs Revenue Market Share by Region (2019-2024)

    Table 47. APAC Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024) & (K Units)

    Table 48. APAC Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024) & (K Units)

    Table 49. Europe Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)

    Table 50. Europe Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2024)

    Table 51. Europe Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & ($ Millions)

    Table 52. Europe Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2024)

    Table 53. Europe Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024) & (K Units)

    Table 54. Europe Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024) & (K Units)

    Table 55. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Country (2019-2024) & (K Units)

    Table 56. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Market Share by Country (2019-2024)

    Table 57. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue by Country (2019-2024) & ($ Millions)

    Table 58. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue Market Share by Country (2019-2024)

    Table 59. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Type (2019-2024) & (K Units)

    Table 60. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales by Application (2019-2024) & (K Units)

    Table 61. Key Market Drivers & Growth Opportunities of Chronic Hepatitis B Oral Drugs

    Table 62. Key Market Challenges & Risks of Chronic Hepatitis B Oral Drugs

    Table 63. Key Industry Trends of Chronic Hepatitis B Oral Drugs

    Table 64. Chronic Hepatitis B Oral Drugs Raw Material

    Table 65. Key Suppliers of Raw Materials

    Table 66. Chronic Hepatitis B Oral Drugs Distributors List

    Table 67. Chronic Hepatitis B Oral Drugs Customer List

    Table 68. Global Chronic Hepatitis B Oral Drugs Sales Forecast by Region (2025-2030) & (K Units)

    Table 69. Global Chronic Hepatitis B Oral Drugs Revenue Forecast by Region (2025-2030) & ($ millions)

    Table 70. Americas Chronic Hepatitis B Oral Drugs Sales Forecast by Country (2025-2030) & (K Units)

    Table 71. Americas Chronic Hepatitis B Oral Drugs Revenue Forecast by Country (2025-2030) & ($ millions)

    Table 72. APAC Chronic Hepatitis B Oral Drugs Sales Forecast by Region (2025-2030) & (K Units)

    Table 73. APAC Chronic Hepatitis B Oral Drugs Revenue Forecast by Region (2025-2030) & ($ millions)

    Table 74. Europe Chronic Hepatitis B Oral Drugs Sales Forecast by Country (2025-2030) & (K Units)

    Table 75. Europe Chronic Hepatitis B Oral Drugs Revenue Forecast by Country (2025-2030) & ($ millions)

    Table 76. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Forecast by Country (2025-2030) & (K Units)

    Table 77. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue Forecast by Country (2025-2030) & ($ millions)

    Table 78. Global Chronic Hepatitis B Oral Drugs Sales Forecast by Type (2025-2030) & (K Units)

    Table 79. Global Chronic Hepatitis B Oral Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)

    Table 80. Global Chronic Hepatitis B Oral Drugs Sales Forecast by Application (2025-2030) & (K Units)

    Table 81. Global Chronic Hepatitis B Oral Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)

    Table 82. GSK Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 83. GSK Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 84. GSK Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 85. GSK Main Business

    Table 86. GSK Latest Developments

    Table 87. Bristol Myers Squibb Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 88. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 89. Bristol Myers Squibb Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 90. Bristol Myers Squibb Main Business

    Table 91. Bristol Myers Squibb Latest Developments

    Table 92. Gilead Sciences Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 93. Gilead Sciences Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 94. Gilead Sciences Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 95. Gilead Sciences Main Business

    Table 96. Gilead Sciences Latest Developments

    Table 97. Novartis Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 98. Novartis Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 99. Novartis Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 100. Novartis Main Business

    Table 101. Novartis Latest Developments

    Table 102. Roche Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 103. Roche Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 104. Roche Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 105. Roche Main Business

    Table 106. Roche Latest Developments

    Table 107. Merck Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 108. Merck Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 109. Merck Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 110. Merck Main Business

    Table 111. Merck Latest Developments

    Table 112. Johnson & Johnson Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 113. Johnson & Johnson Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 114. Johnson & Johnson Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 115. Johnson & Johnson Main Business

    Table 116. Johnson & Johnson Latest Developments

    Table 117. Dawnrays Pharmaceutical Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 118. Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 119. Dawnrays Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 120. Dawnrays Pharmaceutical Main Business

    Table 121. Dawnrays Pharmaceutical Latest Developments

    Table 122. Hansoh Pharmaceutical Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 123. Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 124. Hansoh Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 125. Hansoh Pharmaceutical Main Business

    Table 126. Hansoh Pharmaceutical Latest Developments

    Table 127. Chia Tai-Tianqing Pharmaceutical Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 128. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 129. Chia Tai-Tianqing Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 130. Chia Tai-Tianqing Pharmaceutical Main Business

    Table 131. Chia Tai-Tianqing Pharmaceutical Latest Developments

    Table 132. Qilu pharmaceutical Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 133. Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 134. Qilu pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 135. Qilu pharmaceutical Main Business

    Table 136. Qilu pharmaceutical Latest Developments

    Table 137. Fujian Cosunter Pharma Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 138. Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 139. Fujian Cosunter Pharma Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 140. Fujian Cosunter Pharma Main Business

    Table 141. Fujian Cosunter Pharma Latest Developments

    Table 142. Xiamen Amoytop Biotech Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 143. Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 144. Xiamen Amoytop Biotech Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 145. Xiamen Amoytop Biotech Main Business

    Table 146. Xiamen Amoytop Biotech Latest Developments

    Table 147. YaoPharma Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 148. YaoPharma Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 149. YaoPharma Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 150. YaoPharma Main Business

    Table 151. YaoPharma Latest Developments

    Table 152. Kelun Pharmaceutical Basic Information, Chronic Hepatitis B Oral Drugs Manufacturing Base, Sales Area and Its Competitors

    Table 153. Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Product Portfolios and Specifications

    Table 154. Kelun Pharmaceutical Chronic Hepatitis B Oral Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)

    Table 155. Kelun Pharmaceutical Main Business

    Table 156. Kelun Pharmaceutical Latest Developments

List of Figures

    Figure 1. Picture of Chronic Hepatitis B Oral Drugs

    Figure 2. Chronic Hepatitis B Oral Drugs Report Years Considered

    Figure 3. Research Objectives

    Figure 4. Research Methodology

    Figure 5. Research Process and Data Source

    Figure 6. Global Chronic Hepatitis B Oral Drugs Sales Growth Rate 2019-2030 (K Units)

    Figure 7. Global Chronic Hepatitis B Oral Drugs Revenue Growth Rate 2019-2030 ($ Millions)

    Figure 8. Chronic Hepatitis B Oral Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)

    Figure 9. Product Picture of Entecavir

    Figure 10. Product Picture of Tenofovir

    Figure 11. Product Picture of Lamivudine

    Figure 12. Product Picture of Adefovir

    Figure 13. Product Picture of Telbivudine

    Figure 14. Product Picture of Others

    Figure 15. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Type in 2023

    Figure 16. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Type (2019-2024)

    Figure 17. Chronic Hepatitis B Oral Drugs Consumed in Hospital

    Figure 18. Global Chronic Hepatitis B Oral Drugs Market: Hospital (2019-2024) & (K Units)

    Figure 19. Chronic Hepatitis B Oral Drugs Consumed in Clinic

    Figure 20. Global Chronic Hepatitis B Oral Drugs Market: Clinic (2019-2024) & (K Units)

    Figure 21. Chronic Hepatitis B Oral Drugs Consumed in Others

    Figure 22. Global Chronic Hepatitis B Oral Drugs Market: Others (2019-2024) & (K Units)

    Figure 23. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2023)

    Figure 24. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Application in 2023

    Figure 25. Chronic Hepatitis B Oral Drugs Sales Market by Company in 2023 (K Units)

    Figure 26. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Company in 2023

    Figure 27. Chronic Hepatitis B Oral Drugs Revenue Market by Company in 2023 ($ Million)

    Figure 28. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Company in 2023

    Figure 29. Global Chronic Hepatitis B Oral Drugs Sales Market Share by Geographic Region (2019-2024)

    Figure 30. Global Chronic Hepatitis B Oral Drugs Revenue Market Share by Geographic Region in 2023

    Figure 31. Americas Chronic Hepatitis B Oral Drugs Sales 2019-2024 (K Units)

    Figure 32. Americas Chronic Hepatitis B Oral Drugs Revenue 2019-2024 ($ Millions)

    Figure 33. APAC Chronic Hepatitis B Oral Drugs Sales 2019-2024 (K Units)

    Figure 34. APAC Chronic Hepatitis B Oral Drugs Revenue 2019-2024 ($ Millions)

    Figure 35. Europe Chronic Hepatitis B Oral Drugs Sales 2019-2024 (K Units)

    Figure 36. Europe Chronic Hepatitis B Oral Drugs Revenue 2019-2024 ($ Millions)

    Figure 37. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales 2019-2024 (K Units)

    Figure 38. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue 2019-2024 ($ Millions)

    Figure 39. Americas Chronic Hepatitis B Oral Drugs Sales Market Share by Country in 2023

    Figure 40. Americas Chronic Hepatitis B Oral Drugs Revenue Market Share by Country in 2023

    Figure 41. Americas Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

    Figure 42. Americas Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)

    Figure 43. United States Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 44. Canada Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 45. Mexico Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 46. Brazil Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 47. APAC Chronic Hepatitis B Oral Drugs Sales Market Share by Region in 2023

    Figure 48. APAC Chronic Hepatitis B Oral Drugs Revenue Market Share by Regions in 2023

    Figure 49. APAC Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

    Figure 50. APAC Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)

    Figure 51. China Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 52. Japan Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 53. South Korea Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 54. Southeast Asia Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 55. India Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 56. Australia Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 57. China Taiwan Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 58. Europe Chronic Hepatitis B Oral Drugs Sales Market Share by Country in 2023

    Figure 59. Europe Chronic Hepatitis B Oral Drugs Revenue Market Share by Country in 2023

    Figure 60. Europe Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

    Figure 61. Europe Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)

    Figure 62. Germany Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 63. France Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 64. UK Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 65. Italy Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 66. Russia Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 67. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Market Share by Country in 2023

    Figure 68. Middle East & Africa Chronic Hepatitis B Oral Drugs Revenue Market Share by Country in 2023

    Figure 69. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Market Share by Type (2019-2024)

    Figure 70. Middle East & Africa Chronic Hepatitis B Oral Drugs Sales Market Share by Application (2019-2024)

    Figure 71. Egypt Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 72. South Africa Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 73. Israel Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 74. Turkey Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 75. GCC Country Chronic Hepatitis B Oral Drugs Revenue Growth 2019-2024 ($ Millions)

    Figure 76. Manufacturing Cost Structure Analysis of Chronic Hepatitis B Oral Drugs in 2023

    Figure 77. Manufacturing Process Analysis of Chronic Hepatitis B Oral Drugs

    Figure 78. Industry Chain Structure of Chronic Hepatitis B Oral Drugs

    Figure 79. Channels of Distribution

    Figure 80. Global Chronic Hepatitis B Oral Drugs Sales Market Forecast by Region (2025-2030)

    Figure 81. Global Chronic Hepatitis B Oral Drugs Revenue Market Share Forecast by Region (2025-2030)

    Figure 82. Global Chronic Hepatitis B Oral Drugs Sales Market Share Forecast by Type (2025-2030)

    Figure 83. Global Chronic Hepatitis B Oral Drugs Revenue Market Share Forecast by Type (2025-2030)

    Figure 84. Global Chronic Hepatitis B Oral Drugs Sales Market Share Forecast by Application (2025-2030)

    Figure 85. Global Chronic Hepatitis B Oral Drugs Revenue Market Share Forecast by Application (2025-2030)

Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
GSK|||Bristol Myers Squibb|||Gilead Sciences|||Novartis|||Roche|||Merck|||Johnson & Johnson|||Dawnrays Pharmaceutical|||Hansoh Pharmaceutical|||Chia Tai-Tianqing Pharmaceutical|||Qilu pharmaceutical|||Fujian Cosunter Pharma|||Xiamen Amoytop Biotech|||YaoPharma|||Kelun Pharmaceutical

Frequently Asked Questions

What is the USP of the report? expand_more
Chronic Hepatitis B Oral Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
Chronic Hepatitis B Oral Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
Chronic Hepatitis B Oral Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.